{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:22:22Z","timestamp":1793391742325,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In salivary gland carcinomas (SGC), there is only a small fraction of entities that appears to profit from immune checkpoint inhibition (ICI). Recent findings connected the activation of adenosine-signaling with a tolerogenic microenvironment. Therefore, the inhibition of adenosine pathway markers (CD39 and\/or CD73) can augment ICI and\/or display a novel immunotherapeutic strategy beyond ICI. Here, we assessed the immuno-histochemical expression of CD39 and CD73 across a wide spectrum of SGCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 114 patients with SGCs consecutively diagnosed between 2001 and 2021 were assessed for clinicopathological baseline characteristics and underwent confirmatory histopathological review. Immunohistochemical expression levels of CD39 and CD73 were assessed by applying the tumor proportion score (TPS) and the immune proportional score (IPS) comparable to PD-L1 expression analysis in routine clinical practice. Additionally, findings were correlated with PD-L1 expression levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age was 60.6 and 51.8% patients were female. The cohort covered a spectrum of eight distinct entities. Advanced-stage disease (UICC\/AJCC III\/IVA-IVC) at initial diagnosis was present in the majority of patients (64\/114). Immunohistochemical staining revealed positivity for CD39 and CD73 in 48.2% and 21.1% on tumor cells (TPS\u2009\u2265\u20091%) as well as 46.4% and 42.9% within the immune cell infiltrate (IPS\u2009\u2265\u20091%), respectively. Further comparative analyses revealed immune-cold entities such adenoid cystic carcinoma (AdCC), immune-hot tumors such as adenocarcinoma, not otherwise specified (AC (NOS)) and entities with intermediate immunologic features such as acinic cell carcinoma (ACC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Current results indicate entity-specific adenosine signaling signatures. These findings suggest that the adenosine pathway plays a decisive role in tumor immunity among the major spectrum of SGCs. Targeting the adenosine pathway might pose a promising therapeutic option for selected entities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04211-x","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T17:02:52Z","timestamp":1659027772000},"page":"3193-3208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition"],"prefix":"10.1007","volume":"149","author":[{"given":"Arthur","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Knief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Tharun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Riecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Steinestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"4211_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J (2017) The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev 276:121\u2013144. https:\/\/doi.org\/10.1111\/imr.12528","journal-title":"Immunol Rev"},{"key":"4211_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J (2020a) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17:611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"4211_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000186","author":"D Allard","year":"2020","unstructured":"Allard D, Allard B, Stagg J (2020b) On the mechanism of anti-CD39 immune checkpoint therapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000186","journal-title":"J Immunother Cancer"},{"key":"4211_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","journal-title":"Lancet Oncol"},{"key":"4211_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"4211_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, Zhang B (2019) CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 11:983\u2013997. https:\/\/doi.org\/10.2217\/imt-2018-0200","journal-title":"Immunotherapy"},{"key":"4211_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen RB, Delord JP, Doi T et al (2018) Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 41:1083\u20131088. https:\/\/doi.org\/10.1097\/COC.0000000000000429","journal-title":"Am J Clin Oncol"},{"key":"4211_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"4211_CR9","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::aid-cncr2820621110>3.0.co;2-4","volume":"62","author":"ET Creagan","year":"1988","unstructured":"Creagan ET, Woods JE, Rubin J, Schaid DJ (1988) Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 62:2313\u20132319. https:\/\/doi.org\/10.1002\/1097-0142(19881201)62:11%3c2313::aid-cncr2820621110%3e3.0.co;2-4","journal-title":"Cancer"},{"key":"4211_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1186\/s12885-021-08601-1","volume":"21","author":"A De Caluwe","year":"2021","unstructured":"De Caluwe A, Buisseret L, Poortmans P et al (2021) Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. BMC Cancer 21:899. https:\/\/doi.org\/10.1186\/s12885-021-08601-1","journal-title":"BMC Cancer"},{"key":"4211_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0891-5849(93)90174-s","volume":"15","author":"I Durak","year":"1993","unstructured":"Durak I, Isik AC, Canbolat O, Akyol O, Kavutcu M (1993) Adenosine deaminase, 5\u2032 nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in cancerous and noncancerous human laryngeal tissues. Free Radic Biol Med 15:681\u2013684. https:\/\/doi.org\/10.1016\/0891-5849(93)90174-s","journal-title":"Free Radic Biol Med"},{"key":"4211_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4211_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature08296","volume":"461","author":"MR Elliott","year":"2009","unstructured":"Elliott MR, Chekeni FB, Trampont PC et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282\u2013286. https:\/\/doi.org\/10.1038\/nature08296","journal-title":"Nature"},{"key":"4211_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.humpath.2017.05.014","volume":"66","author":"AK El-Naggar","year":"2017","unstructured":"El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ (2017) The fourth edition of the head and neck World Health Organization blue book: editors\u2019 perspectives. Hum Pathol 66:10\u201312. https:\/\/doi.org\/10.1016\/j.humpath.2017.05.014","journal-title":"Hum Pathol"},{"key":"4211_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF02782198","volume":"17","author":"A Eroglu","year":"2000","unstructured":"Eroglu A, Canbolat O, Demirci S, Kocaoglu H, Eryavuz Y, Akgul H (2000) Activities of adenosine deaminase and 5\u2032-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol 17:319\u2013324. https:\/\/doi.org\/10.1007\/BF02782198","journal-title":"Med Oncol"},{"issue":"15_Suppl","key":"4211_CR16","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","volume":"37","author":"JEC Fayette","year":"2019","unstructured":"Fayette JEC, Digue L, Geoffrois L, Rolland F, Cupissol D et al (2019) NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J Clin Oncol 37(15_Suppl):6083","journal-title":"J Clin Oncol"},{"key":"4211_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imlet.2018.03.007","volume":"205","author":"E Ferretti","year":"2019","unstructured":"Ferretti E, Horenstein AL, Canzonetta C, Costa F, Morandi F (2019) Canonical and non-canonical adenosinergic pathways. Immunol Lett 205:25\u201330. https:\/\/doi.org\/10.1016\/j.imlet.2018.03.007","journal-title":"Immunol Lett"},{"key":"4211_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, Hotson A, Powderly JD et al (2020) Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discov 10:40\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0980","journal-title":"Cancer Discov"},{"key":"4211_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","volume":"26","author":"S Goswami","year":"2020","unstructured":"Goswami S, Walle T, Cornish AE et al (2020) Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26:39\u201346. https:\/\/doi.org\/10.1038\/s41591-019-0694-x","journal-title":"Nat Med"},{"key":"4211_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00227","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F et al (2022) COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00227","journal-title":"J Clin Oncol"},{"key":"4211_CR21","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1158\/1538-7445.Am2019-3278","volume":"79","author":"E Houthuys","year":"2019","unstructured":"Houthuys E, Basilico P, Bodo V et al (2019) Abstract 3278: EOS100850 potently restores adenosine A2Areceptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment. Cancer Res 79:3278. https:\/\/doi.org\/10.1158\/1538-7445.Am2019-3278","journal-title":"Cancer Res"},{"key":"4211_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11864-017-0484-y","volume":"18","author":"SH Huang","year":"2017","unstructured":"Huang SH, O\u2019Sullivan B (2017) Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol 18:40. https:\/\/doi.org\/10.1007\/s11864-017-0484-y","journal-title":"Curr Treat Options Oncol"},{"key":"4211_CR23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","volume":"70","author":"D Jin","year":"2010","unstructured":"Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70:2245\u20132255. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3109","journal-title":"Cancer Res"},{"key":"4211_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12105-017-0796-z","volume":"11","author":"N Katabi","year":"2017","unstructured":"Katabi N, Lewis JS (2017) Update from the 4th edition of the World Health Organization Classification of head and neck tumours: what is new in the 2017 WHO blue book for tumors and tumor-like lesions of the neck and lymph nodes. Head Neck Pathol 11:48\u201354. https:\/\/doi.org\/10.1007\/s12105-017-0796-z","journal-title":"Head Neck Pathol"},{"key":"4211_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/his.12488","volume":"65","author":"N Katabi","year":"2014","unstructured":"Katabi N, Ghossein R, Ali S, Dogan S, Klimstra D, Ganly I (2014) Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading. Histopathology 65:793\u2013804. https:\/\/doi.org\/10.1111\/his.12488","journal-title":"Histopathology"},{"key":"4211_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","volume":"12","author":"SA Laurie","year":"2011","unstructured":"Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG (2011) Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12:815\u2013824. https:\/\/doi.org\/10.1016\/S1470-2045(10)70245-X","journal-title":"Lancet Oncol"},{"key":"4211_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"RD Leone","year":"2018","unstructured":"Leone RD, Sun IM, Oh MH, Sun IH, Wen J, Englert J, Powell JD (2018) Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother 67:1271\u20131284. https:\/\/doi.org\/10.1007\/s00262-018-2186-0","journal-title":"Cancer Immunol Immunother"},{"key":"4211_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1320011","volume":"6","author":"J Li","year":"2017","unstructured":"Li J, Wang L, Chen X et al (2017) CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology 6:e1320011. https:\/\/doi.org\/10.1080\/2162402X.2017.1320011","journal-title":"Oncoimmunology"},{"key":"4211_CR29","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"XY Li","year":"2019","unstructured":"Li XY, Moesta AK, Xiao C et al (2019) Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov 9:1754\u20131773. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0541","journal-title":"Cancer Discov"},{"key":"4211_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-019-0724-7","volume":"12","author":"XL Ma","year":"2019","unstructured":"Ma XL, Shen MN, Hu B et al (2019) CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K\/AKT signaling by inducing Rap1-mediated membrane localization of P110beta and predicts poor prognosis. J Hematol Oncol 12:37. https:\/\/doi.org\/10.1186\/s13045-019-0724-7","journal-title":"J Hematol Oncol"},{"key":"4211_CR31","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2018.36.15_suppl.4123","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, LoRusso P, Strickler JH et al (2018) Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). J Clin Oncol 36:4123. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4123","journal-title":"J Clin Oncol"},{"issue":"2411\u201325","key":"4211_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M et al (2019) Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27(2411\u201325):e9. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.091","journal-title":"Cell Rep"},{"key":"4211_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","volume":"28","author":"A Pinna","year":"2014","unstructured":"Pinna A (2014) Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28:455\u2013474. https:\/\/doi.org\/10.1007\/s40263-014-0161-7","journal-title":"CNS Drugs"},{"key":"4211_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2021.08.037","volume":"521","author":"EM Ploeg","year":"2021","unstructured":"Ploeg EM, Ke X, Britsch I, Hendriks M, Van der Zant FA, Kruijff S, Samplonius DF, Zhang H, Helfrich W (2021) Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. Cancer Lett 521:109\u2013118. https:\/\/doi.org\/10.1016\/j.canlet.2021.08.037","journal-title":"Cancer Lett"},{"key":"4211_CR35","first-page":"3702","volume":"49","author":"RR Rackley","year":"1989","unstructured":"Rackley RR, Lewis TJ, Preston EM, Delmoro CM, Bradley EL Jr, Resnick MI, Pretlow TP, Pretlow TG (1989) 5\u2032-Nucleotidase activity in prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 49:3702\u20133707","journal-title":"Cancer Res"},{"key":"4211_CR36","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.4317\/jced.54918","volume":"11","author":"MA Ranjbar","year":"2019","unstructured":"Ranjbar MA, Ranjbar Z, Zahed M, Nikookar N (2019) CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors. J Clin Exp Dent 11:e213\u2013e218. https:\/\/doi.org\/10.4317\/jced.54918","journal-title":"J Clin Exp Dent"},{"key":"4211_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537\u2013546. https:\/\/doi.org\/10.1200\/JCO.18.00149","journal-title":"J Clin Oncol"},{"key":"4211_CR38","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","volume":"77","author":"J Reinhardt","year":"2017","unstructured":"Reinhardt J, Landsberg J, Schmid-Burgk JL et al (2017) MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res 77:4697\u20134709. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0395","journal-title":"Cancer Res"},{"key":"4211_CR39","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00262-020-02820-4","volume":"70","author":"P Rocha","year":"2021","unstructured":"Rocha P, Salazar R, Zhang J et al (2021) CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70:1965\u20131976. https:\/\/doi.org\/10.1007\/s00262-020-02820-4","journal-title":"Cancer Immunol Immunother"},{"key":"4211_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","volume":"53","author":"M Roh","year":"2020","unstructured":"Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B (2020) Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol 53:66\u201376. https:\/\/doi.org\/10.1016\/j.coph.2020.07.001","journal-title":"Curr Opin Pharmacol"},{"key":"4211_CR41","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","volume":"39","author":"HU Schildhaus","year":"2018","unstructured":"Schildhaus HU (2018) Der pr\u00e4diktive Wert der PD-L1-Diagnostik. Pathologe 39:498\u2013519. https:\/\/doi.org\/10.1007\/s00292-018-0507-x","journal-title":"Pathologe"},{"key":"4211_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040873","author":"HM Witte","year":"2020","unstructured":"Witte HM, Gebauer N, Lappohn D, Umathum VG, Riecke A, Arndt A, Steinestel K (2020) Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12040873","journal-title":"Cancers (Basel)"},{"key":"4211_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103592","volume":"170","author":"HM Witte","year":"2022","unstructured":"Witte HM, Gebauer N, Steinestel K (2022) Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies. Crit Rev Oncol Hematol 170:103592. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103592","journal-title":"Crit Rev Oncol Hematol"},{"key":"4211_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-19-0749","volume":"8","author":"J Yan","year":"2020","unstructured":"Yan J, Li XY, Roman Aguilera A et al (2020) Control of metastases via myeloid CD39 and NK cell effector function. Cancer Immunol Res 8:356\u2013367. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0749","journal-title":"Cancer Immunol Res"},{"key":"4211_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS et al (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30:391\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025","journal-title":"Cancer Cell"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04211-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04211-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04211-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:07:23Z","timestamp":1688213243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04211-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4211"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04211-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}